Electrical bioimpedance for AML and MDS patients
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at a new way to measure body fluids and tissues using a safe, painless electrical signal, to see if it can help doctors better understand AML and MDS. It involves a simple test along with your regular bone marrow biopsy and might help guide future treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with or are suspected of having AML (acute myeloid leukemia) or MDS (myelodysplastic syndrome)
- You are scheduled to have a bone marrow biopsy as part of your care
- You can give informed consent (agree to take part after understanding the details)
- You do not have any electronic implants (like pacemakers, nerve stimulators, or insulin pumps)
- You are not pregnant
- You can communicate in English or Spanish
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how a certain biological pathway (called BMP) affects the progression of blood cancers like MDS and AML. By understanding this, doctors hope to find better ways to predict or treat these conditions.
This study tests a new lab method to screen for acute myeloid leukemia (AML), including a rare subtype called acute promyelocytic leukemia. It may help doctors diagnose and classify AML more quickly and accurately.
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
This study uses blood samples from people with acute myeloid leukemia (AML) and from healthy stem cell donors to learn how to make immune cells better at killing cancer. The goal is to develop a new type of treatment that helps the body's own defenses fight the disease.
This study checks for “minimal residual disease,” meaning tiny numbers of leukemia cells that can remain after treatment. Results may help doctors better monitor your response and risk of relapse in AML or high-risk MDS.
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.